secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263536
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q3 net loss $112.7M; cash $1.1B; BEAM-302 expands; Orbital acquisition by BMS
--------------------------------------------------------------------------------

- Net loss of $112.7M ($1.10 per share) in Q3 2025 vs $96.7M ($1.17 per share) in Q3 2024.
- Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2025, up from $850.7M at Dec 31, 2024; runway into 2028.
- BEAM-302 expanded: multi-dose cohort (60 mg x2, 8 wks apart) in Part A; first patient dosed in Part B (liver disease). Data in early 2026.
- BEAM-101 updated data accepted for ASH Dec 2025; FDA granted RMAT designation in Aug 2025.
- First subject dosed with BEAM-103 (ESCAPE mAb) in Phase 1 HV trial; BMS to acquire Orbital for $1.5B; Beam holds ~17% stake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312525263536/0001193125-25-263536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312525263536/beam-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer